Beta Blockers in Patients with Emphysema
Safety and Selection Considerations
- Cardioselective beta blockers, such as bisoprolol, metoprolol, or nebivolol, are preferred for patients with emphysema as they have minimal effect on bronchial smooth muscle compared to non-selective agents, according to the European Society of Cardiology 2
- Beta blockers should be used with great caution or not at all in patients with persistent symptoms of reactive airway disease, but may be considered in patients with stable emphysema, as recommended by the American Heart Association 3, 4
- Non-selective beta blockers may induce bronchospasm and are not recommended for patients with emphysema, as stated by the European Respiratory Society 2
Initiation and Monitoring Protocol
- Begin with very low doses of a cardioselective agent and gradually uptitrate while monitoring for respiratory symptoms, as suggested by the American College of Cardiology 3, 4
- Monitor patients closely for changes in vital signs, symptoms, and lung function during the uptitration period, according to the European Society of Cardiology 5
- Watch for warning signs including new or worsening shortness of breath and increased cough, as indicated by the European Heart Journal 1
Evidence Supporting Use
- A meta-analysis demonstrated that beta blockers, particularly cardioselective agents, in patients with COPD and cardiovascular disease reduce all-cause and in-hospital mortality, as reported by the American Heart Association 2
Important Caveats and Contraindications
- Beta blockers should not be initiated in patients with active bronchospasm or during an acute exacerbation, as recommended by the American College of Chest Physicians 3, 4
- Beta blockers are contraindicated in patients with a history of asthma, according to the Global Initiative for Asthma 6
- Beta blockers should not be initiated in patients with severe uncompensated heart failure, as stated by the European Society of Cardiology 5